T he majority of human genes express more than one RNA isoform, resulting from alternative sites of splicing, transcriptional initiation and termination. Alternative splicing can generate diversity at the RNA and protein levels, which is important for many biological processes 1 . Aberrations in alternative splicing are also implicated in human cancers, resulting from somatic mutations in genes encoding RNA-splicing proteins or in splicing regulatory motifs within exons and introns, and/or altered expression of RNA-binding proteins. The importance of optimal RNA splicing and isoform expression in chronic lymphocytic leukaemia, myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) is evident from the frequent occurrence of mutations in genes encoding RNA splicing factors [2] [3] [4] [5] [6] [7] [8] [9] . Although relatively uncommon in solid tumours, around 50% of people with MDS harbour mutations in RNA splicing factors 10, 11 . Despite many advances in understanding the role of RNA splicing factors in haematopoiesis, how mutations in RNA splicing genes contribute to cancer is unclear.
T he majority of human genes express more than one RNA isoform, resulting from alternative sites of splicing, transcriptional initiation and termination. Alternative splicing can generate diversity at the RNA and protein levels, which is important for many biological processes 1 . Aberrations in alternative splicing are also implicated in human cancers, resulting from somatic mutations in genes encoding RNA-splicing proteins or in splicing regulatory motifs within exons and introns, and/or altered expression of RNA-binding proteins. The importance of optimal RNA splicing and isoform expression in chronic lymphocytic leukaemia, myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) is evident from the frequent occurrence of mutations in genes encoding RNA splicing factors [2] [3] [4] [5] [6] [7] [8] [9] . Although relatively uncommon in solid tumours, around 50% of people with MDS harbour mutations in RNA splicing factors 10, 11 . Despite many advances in understanding the role of RNA splicing factors in haematopoiesis, how mutations in RNA splicing genes contribute to cancer is unclear.
A subset of leukaemia-associated genes is regulated at the expression level, a result of coordinated change in all of the individual isoforms of these genes, typically due to use of alternative transcriptional-start sites. However, we posited that a subset of genes is regulated exclusively at the isoform level in leukaemia, resulting in anticorrelated expression of the individual RNA isoforms.
Here we used a global analysis of exon usage in AML to reveal enrichment of genes associated with inflammatory and immune pathways that are regulated by RNA isoform changes. Of the inflammatory and immune pathway genes undergoing RNA isoform switching in MDS and AML, isoform expression of interleukin-1 receptor-associated kinase 4 (IRAK4) was the most markedly altered. In MDS and AML, a long isoform of the protein (IRAK4-L) is expressed and physically associates with MyD88, resulting in activation of nuclear factor kappa-light-chain-enhancer of B cells (NF-κB) and mitogen-activated protein kinase (MAPK). We also demonstrated that expression of IRAK4-L is directly mediated by the mutant U2 small nuclear RNA auxiliary factor 1 (U2AF1) splicing factor in MDS and AML. Inhibition of IRAK4 abrogates leukaemic growth and is more efficacious in AML cells with U2AF1 mutations and/or increased expression of IRAK4-L. In sum, we show that mutations in U2AF1 induce expression of therapeutically targetable active IRAK4 isoforms and provide a genetic link to activation of chronic innate immune signalling in MDS and AML. and changes in global gene expression 10, 12, 13 . As a complementary approach, we investigated whether differential expression of RNA isoforms and alternative splicing are sufficient to distinguish clinically relevant molecular subtypes of AML and reveal oncogenic signalling dependencies ( Supplementary Fig. 1a ). To determine the prevalence of differential RNA isoforms in AML, we analysed RNA-sequencing data from The Cancer Genome Atlas (TCGA). First, we identified genes that were explicitly regulated at the level of . Sashimi plots represent junction reads in representative AML samples. Exon 4 reads were normalized to the total number of reads in each sample and plotted as a ratio (inclusion/total and exclusion/ total). f, Cumulative expression of IRAK4-L and IRAK4-S in individuals with AML (data from TCGA). Patients are ordered according the relative expression of IRAK4-L versus IRAK4-S. g, Relative expression of IRAK4-L to IRAK4-S in normal bone marrow (n = 4) and AML samples (TCGA; n = 160) is shown as box plots including the mean and top and bottom quartiles. The whiskers extend to the highest and lowest observations. Outliers are shown as individual points. HC, healthy controls. Wilcoxon test, P = 0.07. h, PCR with reverse transcription (RT-PCR) of IRAK4-L/S using primers flanking exon 4. Quantification of IRAK4 exon 4 inclusion calculated as the ratio of IRAK4-L versus both isoforms is shown below (three independent experiments). i, Immunoblot of IRAK4 using an N-terminal antibody that recognizes IRAK4-L and a C-terminal antibody that recognizes IRAK4-L and IRAK4-S (three independent experiments). j, Immunoblot of IRAK4 in AML patient samples (AML1 and AML2) and healthy samples. CB, cord blood; BM-CD34 + , CD34 + bone marrow cells; BM-MNC, bone marrow mononuclear cells. Healthy samples were collected from independent donors. The percentage of IRAK4-L out of total IRAK4 isoforms is shown below the blot. The pathway scores were calculated by NetWalker 51 on the basis of a random walk method 52 . The scores directly reflect the enrichment of the indicated pathways for high (positive scores) or low (negative scores) expression of IRAK4-L. The pathways shown here were the highest-scoring pathways. b, HEK293 cells transfected with vector (pcDNA3.1), Flag-tagged IRAK4-L or IRAK4-S for 24 h and immunoblotted for the indicated NF-κB and MAPK proteins (three independent experiments). c, Densiometric analysis of the blot in b. One-sided t-tests. d,e, NF-κB (d) and AP1 (e) activation was measured by κB-site and AP1-site containing reporter assays in HEK293 cells transfected with empty vector, IRAK4-L or IRAK4-S. Values are normalized to Renilla luciferase and empty vector (three or six independent experiments, respectively). Two-sided t-tests. f, Representative PCR and immunoblot of THP1 cells following knockdown of both IRAK4-L and IRAK4-S (shIRAK4-L/S) or IRAK4-L only (shIRAK4-L) (three independent experiments). g, NF-κB activation was measured in THP1 cells stably expressing a κB-site containing reporter and shRNAs targeting IRAK4-L (left) or IRAK4-L/S (right) after stimulation with PAM3CSK4 (+, 500 ng ml −1 ; ++, 1,000 ng ml −1 ; three or five independent experiments, respectively). Two-sided t-tests were used for statistical analyses. h, Overview of IRAK4-L and IRAK4-S downstream signalling based on a-e . i, Sequence-based prediction of protein-protein and domain-domain interactions using all isoforms of IRAK1, IRAK4 and MyD88. Superscripts indicate distinct RNA isoforms encoding the indicated long or short proteins. j, HEK293 cells transfected with HA-MyD88 and either Flag-IRAK4-L or Flag-IRAK4-S were immunoblotted for HA-MyD88 after Flag immunoprecipitation (representative of two independent experiments). k, TF1 and HL60 cells were immunoblotted for IRAK4 with C-terminal IRAK4 antibody after immunoprecipitation of MyD88 (representative of two independent experiments). a IgG bands. All data are mean ± s.e.m. messenger RNA isoform switching. A gene was deemed to be regulated at the level of mRNA isoform switching when at least two of its RNA isoforms exhibited a mutually exclusive expression pattern (expression correlation less than −0.4) and higher isoform-level expression variance compared with gene-level expression variance ( Supplementary Fig. 1b) . On the basis of these criteria, we identified 887 genes that showed patterns of RNA isoform switching ( Fig. 1a and Supplementary Table 1) . A semi-unsupervised hierarchical cluster analysis revealed three groupings of AML characterized by distinct patterns of differential isoform expression of these genes. The three groupings have distinct clinical outcomes, with group 2 having the worst prognosis (Fig. 1b and Supplementary  Fig. 1c ). To identify alternative exon-level expression events that confer worse prognosis, individual exon inclusion or exclusion events for these genes were correlated with overall survival using a multivariate Cox regression analysis. We identified a subset of genes undergoing mRNA isoform switching with a least one differential exon inclusion or exclusion event that significantly correlated with AML survival in patients from group 2 (Supplementary Table 2 ). Functional enrichment analysis revealed that the genes in which differential exon usage correlates with worse AML prognosis are enriched for genes involved in RNA splicing pathways and innate immune and NF-κB signalling ( Fig. 1c and Supplementary Table 3) .
Results

RNA isoforms define
Dysregulation of immune-related genes is widely reported in MDS and AML; however, the precise changes that drive innate immune signalling in MDS or AML haematopoietic stem cells (HSC) remain largely unknown 14 . Therefore, we decided to focus on RNA isoform switching of genes involved in innate immune and NF-κB signalling. Among these genes, IRAK4 emerged as the leading candidate RNA isoform-switching gene since the magnitude of IRAK4 isoform switching was highly significant among AML samples and the inclusion of exon 4 alone correlated with worse outcome (Fig. 1d and Supplementary Fig. 1d ). IRAK4 is a serine/ threonine kinase that mediates signalling downstream of the Tolllike receptor (TLR) superfamily, resulting in NF-κB and MAPK activation 15 . IRAK4 protein consists of a death domain (residues 1-125), a hinge domain (residues 140-150) and a kinase domain (residues 150-460). In AML, IRAK4 is represented by two major protein isoforms, defined by the inclusion or the exclusion of exon 4 in the mRNA (based on NCBI RefSeq annotation, or exon 6 according to AltAnalyze Ensembl 72 annotation; Fig. 1e ). Inclusion of exon 4 is predicted to encode the longer 460-residue IRAK4-L protein, which contains the three main functional domains. Exclusion of exon 4 is predicted to result in utilization of an alternative translational start site, encoding a shorter 336-residue IRAK4 protein lacking the N-terminal death domain (IRAK4-S) (Fig. 1e) .
Expression of IRAK4-L is associated with AML. We next compared IRAK4 exon 4 usage in AML and normal haematopoietic cells using RNA-sequencing data from AML and normal bone marrow samples. Although the cumulative expression of both IRAK4 isoforms did not significantly differ among patients, more than 50% of cells from patients with AML preferentially expressed IRAK4-L (< 1.25-fold higher expression of IRAK4-L relative to IRAK4-S), whereas 18% preferentially expressed IRAK4-S (Fig. 1f) . As compared with normal bone marrow cells, AML samples exhibit a significantly higher proportion of IRAK4-L expression relative to IRAK4-S (Fig. 1g) . Breast, colon and lung cancer cells also express a higher ratio of IRAK4-L relative to IRAK4-S as compared with normal tissues, indicating that expression of IRAK4-L is associated with oncogenic states (Supplementary Fig. 1e ). To independently verify IRAK4 RNA isoform expression in AML, we examined human AML and MDS cell lines. Sanger sequencing confirmed that both IRAK4 RNA isoforms are expressed ( Fig. 1h and Supplementary Fig. 1f) . Consistent with the finding that AML patients express two major isoforms of IRAK4, MDSL, TF1 and THP1 cells exhibit preferential expression of IRAK4-L, whereas HL60 and F36P cells preferentially express IRAK4-S (Fig. 1h) . By contrast, healthy cord blood and bone marrow CD34
+ cells preferentially express IRAK4-S (Fig. 1h) . As such, a subset of AML is associated with expression of IRAK4-L resulting from inclusion of exon 4, whereas normal bone marrow cells primarily express IRAK4-S as a result of exon 4 exclusion.
To determine whether both IRAK4 RNA isoforms encode proteins in AML, we examined IRAK4 protein expression in MDS and AML cell lines using an antibody that recognizes a C-terminal epitope present on both IRAK4 isoforms. In agreement with the RNA isoform expression analysis, MDSL, TF1 and THP1 cells exhibit preferential expression of the longer IRAK4 isoform (IRAK4-L, molecular mass ~50 kDa) whereas HL60 and F36P primarily express a shorter IRAK4 protein isoform (IRAK4-S, molecular mass ~37 kDa), which is not recognized by an antibody that recognizes an N-terminal epitope (Fig. 1i) . F36P cells express a moderately smaller IRAK4 protein (~32 kDa), corresponding to an isoform that includes a second minor downstream open reading frame. Although expression of IRAK4-L differed between the AML cell lines, expression of MyD88 and IRAK1 was comparable across the AML cell lines (Fig. 1i) . Primary AML cells also expressed IRAK4-L, whereas normal bone marrow-derived CD34
+ haematopoietic cells and mononuclear cells predominantly expressed IRAK4-S (Fig. 1j) . These findings indicate that a significant proportion of AML tumours primarily express the longer IRAK4 RNA and protein isoforms.
IRAK4-L activates innate immune signalling.
To investigate whether IRAK4-L expression is correlated with distinct gene-regulatory networks in AML, RNA-sequencing data was examined in patients with AML who were stratified on the basis of the expression of IRAK4-L and IRAK4-S. Gene ontology and pathway analysis revealed that AML samples expressing IRAK4-L (top 25%) are significantly enriched in inflammatory and TLR-signalling signatures as compared with AML samples expressing IRAK4-S (bottom 25%), suggesting that IRAK4-L could be a feed-forward activation node of oncogenic innate immune signalling ( Fig. 2a and Supplementary  Fig. 2a ). To test whether the IRAK4 isoforms exert differential effects on innate immune signalling, we expressed IRAK4-L or IRAK4-S in HEK293 cells and evaluated NF-κB and MAPK activation. Expression of IRAK4-L resulted in increased phosphorylation of IRAK1, p65, p38 and JNK (Fig. 2b,c and Supplementary  Fig. 2b,c) . By contrast, expression of IRAK4-S resulted in phosphorylation of p38 and JNK, but was less efficient at inducing phosphorylation of IRAK1 and p65. IRAK4-L expression also induced increased NF-κB and AP1-dependent transcriptional activation relative to control cells, whereas IRAK4-S induced AP1-dependent activation, but was less efficient at inducing NF-κB-dependent activation (Fig. 2d,e) . Expression of IRAK4-L in HL60 cells, which primarily express IRAK4-S, resulted in activation of IRAK1 and p65, suggesting that IRAK4-L is sufficient to activate NF-κB in AML cells ( Supplementary Fig. 2d ). To determine whether IRAK4-L and/or IRAK4-S are required to activate NF-κB activation, THP1 cells expressing an NF-κB reporter were transduced with short hairpin Fig. 2f ). Knockdown of IRAK4-L resulted in suppression of NF-κB activation at levels similar to simultaneous knockdown of both IRAK4-L and IRAK4-S, indicating that IRAK4-S does not contribute substantially to NF-κB activation in AML (Fig. 2g ). These findings show that MAPK signalling is mediated by the C-terminal domain of IRAK4-S and IRAK4-L, whereas NF-κB signalling is mediated by the N-and C-terminal domains of IRAK4-L (Fig. 2h) .
To further examine differences in NF-κB signalling between IRAK4-L and IRAK4-S, we performed a sequence-based prediction of protein-protein and domain-domain interactions 16 . IRAK4-L protein isoforms, which retain the N-terminal death domain, are predicted to directly bind MyD88 and IRAK1 (Fig. 2i) . Death-domain interactions between MyD88 and IRAK4 initiate myddosome formation, which promotes IRAK4 trans-autophosphorylation and activation 17, 18 . IRAK4 then activates IRAK1, enabling recruitment of TRAF6 and NF-κB activation. On the basis of these predictions, IRAK4-S protein isoforms, which lack the N-terminal death domain, are predicted to not bind MyD88 (Fig. 2i) . To confirm this, Flag-IRAK4-L or Flag-IRAK4-S were expressed in HEK293 cells also expressing haemagglutinin (HA)-tagged MyD88; IRAK4-L or IRAK4-S were then immunoprecipitated via the Flag tag. MyD88 was found to bind IRAK4-L; however, it was less efficient at binding to IRAK4-S (Fig. 2j) . The interaction between IRAK4 isoforms and MyD88 was also confirmed in AML cells that primarily express IRAK4-L (TF1) or IRAK4-S (HL60). Immunoprecipitation of endogenous MyD88 from TF1 and HL60 cells resulted in binding of MyD88 to IRAK4-L (Fig. 2k) . By contrast, IRAK4-S did not co-immunoprecipitate with MyD88 in HL60 cells ( Fig. 2k and Supplementary Fig. 2e ). Thus, IRAK4-L mediates maximal activation of NF-κB signalling through stochastic assembly of the myddosome complex in AML, whereas IRAK4-S exhibits reduced NF-κB activation resulting from diminished MyD88 binding.
IRAK4-L expression is required for leukaemic cell function.
The requirement for IRAK4-L in AML was determined using shIRAK4-L or shIRAK4-L/S (Fig. 3a) . THP1 cells, which express both IRAK4 isoforms, were transduced with shIRAK4-L or shIRAK4-L/S (Fig. 2f) . Knockdown of IRAK4-L was sufficient to impair the leukaemic progenitor function of THP1 cells, as evidenced by formation of fewer colonies in methylcellulose-based medium (Fig. 3b) . THP1 cells expressing shIRAK4-L or shIRAK4-L/S were xenografted ) and from patients with mutation in U2AF1 (MDS-U2AF1 mut ) based on RNA-sequencing junction reads. Quantification of the junction reads for exon 4 are shown for healthy controls (n = 7 samples), MDS-SF WT (n = 6 samples), and MDS-U2AF1 mut (n = 6 samples). Exon 4 inclusion and exclusion reads were normalized to the total number of reads in each sample and plotted as a ratio (inclusion/total and exclusion/total). Two-sided t-tests. c, RT-PCR analysis of healthy CD34
+ cells (n = 7 samples), CD34 + cells isolated from MDS patients with no splicing factor mutations (MDS-SF WT ; n = 17 samples) and from patients with mutation in U2AF1 (MDS-U2AF1 mut ; n = 5 samples) using primers flanking IRAK4 exon 4. Densitometric quantification of IRAK4 exon 4 inclusion calculated as the ratio of the long isoform versus both isoforms is shown below each sample. d, Densitometric quantification of IRAK4 exon 4 inclusion is summarized from data in c. The number in parentheses indicates the number of samples exhibiting > 10% expression of IRAK4-L relative to all IRAK4 isoforms. Two-sided t-tests. e, Consensus sequence motifs identified at the distal 3′ splice sites of exon exclusion events in U2AF1(S34F) cells as compared with U2AF1 using publicly available data and visualized with weblogo software. Above the U2AF1(S34F) consensus motifs is the sequence of the distal 3′ splice site of IRAK4 exon 4. All data are mean ± s.e.m.
into NSG mice and examined for leukaemic burden (Fig. 3a) ; knockdown of IRAK4-L in THP1 cells was sufficient to reduce leukaemic burden in the xenografted mice (Fig. 3c,d ). The antileukaemic effects of knocking down IRAK4-L and IRAK-S was similar to that seen with knockdown of IRAK4-L alone, suggesting that IRAK4-L is the dominant isoform in leukaemic cells (Fig. 3b-d) . As an orthogonal approach, all IRAK4 isoforms were deleted in THP1 cells using clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9) gene editing ( Supplementary Fig. 3a,b) . Deletion of IRAK4-L and IRAK4-S in THP1 cells (THP1-IRAK4 KO) resulted in reduction of leukaemic colony formation in methylcellulose-based medium ( Supplementary Fig. 3c) . Although knockdown or knockout (KO) of IRAK4 isoforms did not affect the growth and/or viability of THP1 cells when cultured in liquid medium ( Supplementary  Fig. 3d-f) , deletion of IRAK4 resulted in increased expression of the monocyte-differentiation marker CD14 and a corresponding decrease in the haematopoietic-stem/progenitor marker CD34 ( Supplementary Fig. 3g ), suggesting that IRAK4-L is required for maintaining a primitive haematopoietic state in THP1 cells. Reduced expression of IRAK4-L (using shIRAK4-L) or in combination with IRAK4-S (using shIRAK-L/S) did not impair the progenitor function of normal CD34
+ cells, but rather resulted in a moderate increase in myeloid and erythroid progenitor colonies 53 and expressed in HEK293 cells (HEK293-IRAK4exon4). c, Representative PCR of IRAK4 exon 4 splicing in HEK293-IRAK4exon4 expressing U2AF1 and U2AF1(S34F) (five independent experiments for AAG; two independent experiments for TAG). d, Top: experimental design to measure IRAK4 RNA and protein isoform expression in K562 cell lines that have stably integrated doxycycline-inducible Flag-U2AF1 or Flag-U2AF1(S34F). Bottom: IRAK4 RNA isoform expression was measured using primers flanking exon 4 in doxycycline (DOX)-induced K562 cells expressing Flag-U2AF1 or Flag-U2AF1(S34F). The top band indicates IRAK4-L, and the bottom band indicates IRAK4-S (five independent experiments). e, IRAK4 protein isoform expression analysed with a C-terminal IRAK4 antibody in doxycycline-induced K562 cells expressing Flag-U2AF1 or Flag-U2AF1(S34F) (three independent experiments). f, The indicated NF-κB and MAPK protein expression was measured in doxycycline-induced K562 cells expressing Flag-U2AF1 or Flag-U2AF1(S34F) by immunoblotting (two independent experiments). g, Expression of the indicated NF-κB (TNFAIP3, IL6, CXCL2 and CXCL8) and MAPK target genes (JUN and EGR1) was measured in doxycycline-induced K562 cells expressing Flag-U2AF1 or Flag-U2AF1(S34F) after IL-1β stimulation (10 ng ml −1 ) for 30 or 60 min (three independent experiments). Two-sided t-tests. All data are mean ± s.e.m. (Fig. 3e ). These findings demonstrate the requirement of IRAK4-L specifically in leukaemia-propagating or initiating cells.
To corroborate the requirement for IRAK4 isoforms in AML, IRAK4-L or IRAK4-S were re-expressed into THP1-IRAK4 KO cells (Fig. 3f) . Expression of IRAK4-L in THP1-IRAK4 KO cells restored the leukaemic progenitor function to a level comparable with control THP1 cells (THP1 + vector) (Fig. 3g,h ). By contrast, IRAK4-S was unable to rescue the leukaemic-progenitor defect of THP1-IRAK4 KO cells (Fig. 3g,h) . As a complimentary approach, restoration of IRAK4-L in THP1 cells expressing shRNAs targeting both IRAK4 isoforms (shIRAK4-L/S) resulted in leukaemic colony formation comparable to that observed in THP1 cells transduced with control shRNA, whereas IRAK4-S was unable to rescue the leukaemic progenitor defect in THP1 cells expressing shIRAK4-L/S ( Supplementary Fig. 4a-c) . We then investigated whether IRAK4 kinase activity was required for leukaemic cells expressing IRAK4-L using an ATP-competitive IRAK4 kinase inhibitor (CA-4948) that is approved for clinical use (NCT03328078) 19 . MDSL, TF1 and THP1 cells, which preferentially express IRAK4-L, formed fewer leukaemic-progenitor colonies with CA-4948 (Fig. 3i) . By contrast, HL60, F36P and normal CD34
+ cells, which express IRAK4-S, were not affected by treatment with CA-4948 (Fig. 3i) . Thus, inhibition of IRAK4 kinase activity in MDS or AML cell lines that express IRAK4-L resulted in diminished leukaemic function in vitro relative to cells that preferentially express IRAK4-S (Fig. 3j) . To demonstrate that IRAK4 inhibition can suppress leukaemic cell function in vivo, THP1 cells were xenografted into NSG mice. Following treatment with IRAK4 inhibitor (Fig. 3k) , THP1 infiltration in the bone marrow, spleen and liver was reduced compared with mice receiving vehicle control (Fig. 3l,m) . Collectively, these results establish that IRAK4-L, but not IRAK4-S, signalling programmes are required for leukaemia-propagating cells, and that inhibition of IRAK4 abrogates leukaemic growth in AML cells expressing IRAK4-L.
IRAK4-L is associated with U2AF1 mutations in MDS/AML.
We next sought to identify the genetic alterations associated with inclusion of IRAK4 exon 4 in AML. Among all patients with AML examined in TCGA, inclusion of IRAK4 exon 4 was significantly correlated with mutations in U2 small nuclear RNA auxiliary factor 1 (U2AF1), a gene encoding an RNA-binding protein critical for 3′ splice-acceptor site recognition in pre-mRNAs (Fig. 4a) . Given the prevalence of U2AF1 mutations in MDS, we examined IRAK4 exon 4 usage in MDS CD34 + cells. All of the patients with MDS with U2AF1 mutations (S34F, R156H and Q157P/R) expressed IRAK4-L (6 of 6 by RNA sequencing; and 5 of 5 by RT-PCR), whereas 9 of 17 (52%) patients with MDS without splicing-factor mutations expressed IRAK4-L (MDS-SF wild type) (Fig. 4b-d) . By contrast, less than 20% of healthy age-matched CD34
+ bone marrow cells expressed IRAK4-L (Fig. 4b-d) . As observed in AML, MDS patients expressing increased levels of IRAK4-L had a worse prognosis compared to MDS patients with lower levels of IRAK4-L (ref. 20 and Supplementary Fig. 4d ). The consensus sequence flanking the adenine-guanine dinucleotide at the 3′ splice-acceptor site is recognized by U2AF1 and impacts exon usage by the U2AF1 mutants 21, 22 . A cytosine (C) or adenine (A) at the −3 position correlates with exon inclusion by U2AF1(S34F) relative to wild-type U2AF1 23, 24 . The −3 position of IRAK4 exon 4 contains an adenine, supporting the model in which U2AF1(S34F) mediates exon inclusion (Fig. 4e) . Moreover, the +1 position of IRAK4 exon 4 contains a guanine, which is associated with exon inclusion of U2AF1(Q157X) relative to wild-type U2AF1 21 . These findings suggest that mutant U2AF1 correlates with inclusion of exon 4 and preferential expression of IRAK4-L in AML and CD34
+ MDS cells.
U2AF1(S34F) induces IRAK4-L expression.
To investigate whether mutant U2AF1 directly regulates IRAK4 exon 4 usage and expression of IRAK4-L, RNA sequencing was performed on healthy CD34 + cells expressing wild-type U2AF1 or U2AF1(S34F) (Fig. 5a ). Of note, expression of U2AF1(S34F) resulted in increased reads at the IRAK4 exon 3-exon4 junction compared with U2AF1(WT), indicating that the mutant U2AF1 mediates inclusion of exon 4 (ref. 25 and Fig. 5a ). To gain further insight into the regulation of IRAK4 exon 4, we generated an IRAK4 exon 4 cassette splicing reporter (HEK293-IRAK4exon4, Fig. 5b) . A mutant version of the IRAK4 exon 4 cassette (TAG) was also generated, with a thymine (T) in place of adenine (A) at the −3 position (AAG) since U2AF1(S34F) mediates exon inclusion in the presence of AAG but not TAG (Fig. 5b) . Transfection of U2AF1(S34F) into HEK293-IRAK4exon4 cells resulted in increased inclusion of IRAK4 exon 4 from the wild-type AAG splicing reporter (11.7% exon 4 inclusion) compared to U2AF1(WT) (1.3% exon 4 inclusion) or vector-transfected HEK293-IRAK4exon4 cells (1.4% exon 4 inclusion, Fig. 5c ). Conversely, U2AF1(S34F) did not induce inclusion of IRAK4 exon 4 from the mutant TAG splicing reporter (0.4% exon 4 inclusion; n = 2). Therefore, U2AF1(S34F) is likely to mediate inclusion of IRAK4 exon 4 by direct binding. To extend these observations to human AML cells, we used K562 erythroleukaemia cells that express doxycycline-inducible Flag-tagged U2AF1(S34F) or U2AF1(WT) 26 . Expression of U2AF1(WT) with doxycycline did not affect IRAK4 exon 4 usage or protein expression (Fig. 5d,e) . By contrast, expression of U2AF1(S34F) after doxycycline treatment resulted in robust and dose-dependent IRAK4 exon 4 inclusion (Fig. 5d) , which coincided with increased expression of IRAK4-L protein (Fig. 5e ).
Since U2AF1(S34F) expression results in expression of IRAK4-L and expression of IRAK4-L alone is sufficient to mediate activation of innate immune and NF-κB signalling, we investigated the consequences of U2AF1(S34F) expression on NF-κB and MAPK activation in AML cells. Expression of U2AF1(S34F) in K562 cells resulted in activation of MAPK signalling (p-p38 and p-ERK) and NF-κB signalling (p-IRAK1, p-IKK and p-p65) compared with K562 cells expressing U2AF1(WT) (Fig. 5f ). U2AF1(S34F)-expressing K562 cells were also hypersensitive to interleukin-1β (IL-1β) stimulation as indicated by increased expression of NF-κB (TNFAIP3, IL6, CXCL2 and CXCL8) and MAPK (JUN and EGR1) target genes (Fig. 5g) . U2AF1(S34F) is therefore sufficient to induce expression of IRAK4-L and consequently activate the innate immune pathway.
U2AF1(S34F) AML cells are sensitive to IRAK4 inhibitors.
We determined whether inhibiting IRAK4 kinase activity was sufficient to suppress NF-κB and/or MAPK signalling in U2AF1-mutant AML cells expressing IRAK4-L. To inhibit IRAK4 kinase activity, we evaluated two structurally unrelated IRAK4 inhibitors, IRAK1/4-Inh 27 and CA-4948 19 . When K562 cells expressing U2AF1(S34F) (K562-U2AF1(S34F)) were treated with IRAK1/4-Inh, activation of NF-κB signalling was inhibited, as indicated by reduced p-IRAK1 and p-IKK (Fig. 6a,b and Supplementary Fig. 5 ). By contrast, MAPK signalling was not diminished following treatment with IRAK1/4-Inh. These findings suggest that MAPK activation not only occurs downstream of IRAK4-L, but is also secondary to RNA-splicing changes 28 . On the basis of these observations, we reasoned that inhibition of IRAK4-L catalytic function would suppress pro-survival signalling via NF-κB, thus exposing a therapeutic vulnerability in U2AF1-mutant AML/ MDS. IRAK4 inhibitors (IRAK1/4-Inh or CA-4948) exhibited increased cytotoxicity (indicated by increased Trypan blue-positive cells) compared with vehicle towards K562-U2AF1-S34F cells (Fig. 6c) ; these results were corroborated with assays for annexin V and propidium iodide (PI)-positive cells (Fig. 6d,e) . By contrast, K562-U2AF1(WT) cells were not sensitive to the IRAK4 inhibitors (Fig. 6c-e) . In addition, K562-U2AF1(S34F) cells formed fewer leukaemic-progenitor colonies when treated with IRAK4 inhibitors compared to vehicle-treated cells (Fig. 6f) . Next, primary cells derived from patients with MDS or AML with U2AF1 mutations were grown in clonogenic assays after short-interfering RNA (siRNA)-mediated knockdown or pharmacologic inhibition of IRAK4. IRAK4 knockdown and inhibition with CA-4948 both led to enhanced erythroid and myeloid differentiation (Fig. 6g-i and Supplementary Fig. 6a-c) . By contrast, normal CD34 + cells treated with CA-4948 did not exhibit altered differentiation (Supplementary Fig. 6d) .
To determine the efficacy of IRAK4 inhibitors on primary U2AF1-mutant cells in vivo, xenografts from patients with MDS with U2AF1 mutations were established in NSG mice and treated with CA-4948 (12.5 mg per kg (body weight) per d) or vehicle (Fig. 6g) . Whereas vehicle-treated mice exhibited a 3.2-fold increased expansion of xenografted MDS cells in the bone marrow, IRAK4 inhibition led to a 50% decrease in MDS cell engraftment after three weeks of CA-4948 treatment (Fig. 6j,k) . To establish that inhibition of IRAK4 suppresses the function of disease-propagating MDS cells, bone marrow cells were isolated from primary xenografted mice treated with vehicle or CA-4948 for three weeks (from Fig. 6j,k) and then transplanted into secondary recipient NSG mice. Mice transplanted with vehicle-treated MDS cells engrafted into secondary recipient mice (Fig. 6l,m) . By contrast, there was negligible engraftment of CA-4948-treated MDS cells in secondary recipients (Fig. 6l,m) , suggesting that inhibition of IRAK4-L impairs U2AF1-mutant MDS-propagating cells in vivo. In parallel, we evaluated potential haematologic toxicity after repeated administration of CA-4948 in mice. Administration of CA-4948 for 12 weeks in NSG mice did not affect body weight (not shown) or haematologic blood parameters ( Supplementary Fig. 6e ). These findings indicate that U2AF1(S34F)-expressing MDS/AML cells acquire a dependency on IRAK4-L and are sensitive to IRAK4 inhibition.
Discussion
Clinically relevant molecular subtypes of AML were identified on the basis of differential RNA isoform usage. One major subtype of AML was enriched for RNA isoform changes affecting innate immune pathway genes. Among these genes, an isoform of IRAK4 that retains exon 4 and encodes IRAK4-L was expressed in AML and U2AF1-mutant MDS/AML. While consistent with the current paradigm of myddosome signalling, our findings reveal a mechanism by which IRAK4-L is generated by alternative splicing in MDS/AML to mediate maximal activation of NF-κB through MyD88 binding. By contrast, healthy haematopoietic cells primarily express IRAK4-S and have diminished binding to MyD88 and lower NF-κB activation potential. Thus, IRAK4-S is normally expressed to mitigate spurious and/or excessive NF-κB activation as a result of its diminished ability to bind MyD88. This observation may indicate an evolutionarily-conserved mechanism to regulate innate immune responses. Overexpression of immune-related genes is widely reported in MDS and AML 29, 30 , and chronic innate immune pathway activation, predominantly via TLRs, increases the risk of developing myeloid malignancies 31 . A causal role of innate immune pathway activation in MDS or AML is supported by work related to miR-146a and TIFAB, which reside within the deleted region in del(5q) MDS/AML. Deletion of miR-146a and/or TIFAB results in derepression of their targets TRAF6 and IRAK1, and impaired haematopoiesis and bone marrow failure in mice [32] [33] [34] . Phosphorylation of IRAK1 is observed in non-del(5q) MDS/AML and other cancers; however, the mechanism of IRAK1 activation remains unidentified [35] [36] [37] [38] [39] [40] [41] . In some of these cases, we propose that isoform switching from IRAK4-S to IRAK4-L is the molecular basis of IRAK1 activation. While there are examples of indirect mechanisms that result in activation of innate immune signalling in MDS/AML, the present study provides direct genetic evidence, via mutations in the splicing factor U2AF1, linking oncogenic innate immune signalling to IRAK4 activation in MDS/AML. Although all U2AF1-mutant MDS and AML patient samples exhibited expression of IRAK4-L, approximately 50% of remaining MDS and AML samples expressed IRAK4-L, indicating that other genetic and/or molecular mechanisms regulate alternative splicing of IRAK4 and expression of IRAK4-L. IRAK4-L correlated with mutations in U2AF1, but not with other splicing factor mutations in MDS or AML. For example, mutations in SRSF2 also result in activation of NF-κB signalling, but these effects are independent of IRAK4-isoform regulation 42 . Mutations in RNA-splicing factors are the most frequent class of mutation in MDS, and are common in AML 2, 5, 9, [43] [44] [45] . Unsurprisingly, mouse models with splicing-factor gene mutations develop features of MDS 3, 26, [46] [47] [48] [49] . Mutations affecting the genes encoding core spliceosome machinery, such as SF3B1, U2AF1 and SRSF2 do not result in loss-of-function phenotypes, but rather in selective splicing changes due to aberrant splice-site recognition 3, 5, 21, 25, [48] [49] [50] . Although many RNA-splicing changes in U2AF1-mutant cells result in aberrant RNA splicing, non-functional transcripts and/or nonsense-mediated decay, IRAK4 is an example in which mutant U2AF1 generates an isoform with oncogenic activity. Given the prevalence of RNA splicing gene mutations in haematologic malignancies, effective strategies to therapeutically target spliceosome-mutant malignancies are needed. Small-molecule modulators of the spliceosome target normal splicing by interfering with the splicing machinery and altering 3′ splice-site recognition. Our findings suggest an alternative strategy to target U2AF1-mutant MDS/AML by exposing the therapeutic vulnerability of IRAK4-L expression to IRAK1/4 inhibitors. However, elucidating the mechanism of IRAK4-isoform control during normal development, inflammation and in non-splicing-factor mutant cancers will provide better insight into disease conditions and patients most suitable for treatment with IRAK1/4 inhibitors. In sum, we report that mutations in U2AF1 induce expression of targetable active IRAK4 isoforms and provide a genetic link to activation of oncogenic innate immune signalling in MDS and AML.
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Methods
RNA isoform switching, pathway enrichment and mutation analysis in AML.
To identify genes undergoing isoform switching in the TCGA database, we defined four gene-level metrics: (1) cumulative expression (CE) is the sum of individual isoform expression levels for a gene in a given sample; (2) cumulative abundance (CA) measures the average gene CE across samples; (3) cumulative variance (CV) measures the variance in the CE; (4) isoform variance (IV) measures variance in the expression of an individual mRNA isoform; and (5) isoform divergence (ID) measures the most negative correlation (Pearson's r) between the expressions of mRNA isoforms for a given gene. A strong negative ID (for example, <−0.5) indicates that at least two isoforms of a gene have a mutually exclusive expression pattern, and therefore the gene is at least partially regulated at the level of isoform switching where the expression of one mRNA isoform is substituted by another. A three-dimensional plot relating these measures to each other for all genes expressed in AML is shown in Fig. 1a . For pathway enrichment of genes that are regulated at the level of isoform switching, a hypergeometric distribution test was performed. For pathway over-representation profiles of genes that correlate with the expression of IRAK4-L or IRAK4-S in TCGA AML dataset was generated using NetWalker 54 . For analysis of somatic mutations enriched in AML patients with distinct IRAK4 isoforms, correlations of individual exon expression with the indicated mutations in AML were calculated and represented by z-score in a heat map.
Cell lines and human samples. AML cell lines HL60, THP1, F36P and TF1 were purchased from the American Type Culture Collection. MDSL cells were provided by K. Tohyama (Kawasaki Medical School, Okayama, Japan) 55, 56 . Cell lines were cultured in RPMI-1640 medium with 10% FBS and 1% penicillin-streptomycin. MDSL and TF1 cell lines were cultured in the presence of 10 ng ml −1 recombinant human IL-3 (Stem Cell Technologies). Doxycycline-inducible Flag-tagged wild-type U2AF1 or Flag-tagged U2AF1(S34F) lentiviral expression plasmids were previously described 26 . THP1-IRAK4 KO (referred to as clone 14) and the corresponding wild-type THP1 cells were generated as previously described Creation of inducible 3×Flag-U2AF1(S34F) and U2AF1(WT) AML cell lines. A doxycycline-inducible lentiviral expression plasmid was previously described 43 . For better detection of exogenous U2AF1 expression by western blotting, C-terminal 3×Flag-tagged U2AF1(WT) or U2AF1(S34F) was introduced into the plasmid. Lentivirus was generated in 293T cells with the packaging plasmids pMD-G, pMDLg and REV as described previously 26 . Concentrated virus (multiplicity of infection of 3) was used to transduce K562 cells (ATCC, CCL243). Transduced cells (marked by GFP) were isolated by fluorescence-activated cell sorting (FACS). Expression of U2AF1(WT) or U2AF1(S34F) was induced using the indicated concentrations of doxycycline hyclate (Sigma) in water.
Semi-quantitative and quantitative RT-PCR. Total RNA was extracted and purified using Quick-RNA MiniPrep (Zymo research, R1055) and reverse transcription was carried out using SuperScript cDNA Synthesis Kit (Invitrogen) or High-Capacity cDNA Reverse Transcription Kit (Thermo-Fisher). Long and short isoforms of IRAK4 were amplified using primers flanking IRAK4 exon 4 (set 1 forward primer sequence: ATATGTGCGCTGCCTCAATG, reverse primer sequence: GGTAGTGTATTAGCAGTTTTGGG; set 2 forward primer sequence: GCTGCCTCAATGTTGGACTA, reverse primer sequence: TCTGGACTTGAGGAGTCAGG) in a PCR reaction using maxima hotstart PCR Master Mix (Thermo-Fisher) or GeneAmp Fast PCR Master Mix (Applied Biosystems), and PCR products (312 and 166 bp for IRAK4-L, 427 and 281 bp for IRAK4-S) were separated by electrophoresis on a 2% agarose gel. Band intensity was measured with ImageJ. Statistical significance was determined by Kruskal-Wallis one-way analysis of variance followed by Dunn's post hoc test. Quantitative RT-PCR was performed with either Taqman Master Mix (Life Technologies) for TNFAIP3 (Hs00234713_m1), IL6 (Hs99999032_m1) and GAPDH (Hs02758991_g1) or PowerUP SYBR Green Master Mix (Thermo Fischer Scientific) for JUN (forward primer sequence: TCCAAGTGCCGAAAAAGGAAG reverse primer sequence: CGAGTTCTGAGCTTTCAAGGT), EGR1 (forward primer sequence: CTTCAACCCTCAGGC GGACA reverse primer sequence: GGAAAAGCGGCCAGTATAGGT3), CXCL2 (forward primer sequence: CGCCCATGGTTAAGAAAATCA, reverse primer sequence: CCTTCTGGTCAGTTGGATTTGC), CXCL8 (forward primer sequence: CTTGGCAGCCTTCCTGATTT, reverse primer sequence: TTCTTTAGCACTCCTTGGCAAAA). Quantitative RT-PCR was performed on an Applied Biosystems StepOne Plus Real-Time PCR System.
shRNA-mediated and siRNA-mediated knockdown of IRAK4. The pLKO.1 constructs were obtained from the Lentiviral core at CCHMC. Puromycin resistance gene was replaced by GFP. Two independent and validated pLKO.1-shIRAK4 constructs were obtained: TRCN000000063 and TRCN000000065. For siRNA knockdown, a pool of several siIRAK4 were used.
Plasmids and transfection. Flag-IRAK4-L and Flag-IRAK4-S cDNAs were created by custom gene synthesis (IDT). Flag-IRAK4 was cloned into pcDNA3.0 with EcoRI and BamHI, or into pMSCV-pGK-GFP with EcoRI and XhoI. Transfections were performed using TransIT-LT1 transfection reagent (Mirus MIR 2306).
Immunoblotting and flow cytometry. Total protein lysates were obtained from cells by lysing the samples in cold RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and 0.1% SDS), in the presence of phenylmethyl sulfonyl fluoride, sodium orthovanadate, protease and phosphatase inhibitors. Protein concentration was evaluated by a BCA assay (32106, Pierce). The bound proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and analysed by immunoblotting. Western blot analysis was performed with the antibodies listed in Supplementary Table 4 . For apoptosis assay, cells were treated with 10 μM CA-4948 for 48 h, then washed and resuspended in annexin V binding buffer (10 mM HEPES, 140 mM NaCl, 2.5 mM CaCl 2 , pH 7.4). Annexin V-conjugated antibody (1:100) was added to each sample. After a 15 min incubation, propidium iodide (1:100) was added and cells were analysed by flow cytometry. For analysis of haematopoietic cell surface markers, primary cells were collected, washed once with 1× PBS (GE Healthcare Life Sciences), and subsequently stained with conjugated antibodies. The antibodies in Supplementary  Table 4 were used for flow cytometric analysis of human MDS and AML cells. All the flow data were analysed on a BD LSRII or FACSCanto using BD FACSDiva Software and FlowJo 10.4. For shIRAK4-expressing THP1 xenografts, transduced cells were sorted for GFP expression on the SH800S (Sony Biotechnology).
Generation of THP1 CRISPR-Cas9 IRAK4-KO cells. THP1 cells were maintained in RPMI-1640 medium supplemented with 10% FBS. Medium was renewed every 2-3 d. Cells were electroporated using the Invitrogen Neon Transfection system with the following conditions: 1,350 V, 20 ms width, 1 pulse, using 100 µl tip and 2.0 × 10 6 cells per ml in R buffer (Invitrogen). Cells were transfected with 1 µg pSpCas9(BB)-2A-GFP, a plasmid expressing GFP, Cas9 and a sgRNA targeted to exon 6 of IRAK4. Cells were allowed to recover for 72 h in antibiotic-free RPMI-1640 medium supplemented with 10% FBS. GFP-expressing cells were sorted by FACS into 96-well plates containing THP1 cell conditioned medium. Clones were allowed to expand and screened for gene editing by PCR of the targeted region. Clones of interest were sent for Sanger sequencing to confirm a functional KO of IRAK4 exon 6. THP1-IRAK4 KO cells analysed are clone 3.
Rescue experiments in THP1 cells. THP1 cells were transduced with mCherrytagged shRNAs (pLKO.1-mCherry) targeting both IRAK4-L and shIRAK4-S (shIRAK4-L/S), or empty control, sorted for mCherry expression, and then transduced with vector control (pLEGO-GFP), IRAK4-L-GFP or IRAK4-S-GFP constructs and sorted for mCherry or GFP expression. Concurrently, CRISPR-Cas9 generated THP1-IRAK4 KO cells were transduced with vector control (pMSCVpGK-GFP), IRAK4-L-GFP or IRAK4-S-GFP constructs and sorted for GFP expression. Transduced cells were then assessed for clonogenic progenitor function in methylcellulose and for proliferation in liquid culture by Trypan blue exclusion.
Luciferase assay. HEK293 cells were transfected for 24-48 h with κB-luciferase or AP1-luciferase and TK Renilla plasmids along with IRAK4-L or IRAK4-S. Lysates were analysed for NF-κB reporter or AP1 reporter activity using the dual-luciferase reporter assay system (Promega E1910).
NF-κB reporter assay. THP1-Blue NF-κB cells (InvivoGen) carrying a stable integrated NF-κB-inducible secreted embryonic alkaline phosphatase (SEAP) reporter construct were transduced with shIRAK4-GFP and sorted for GFP expression after 48 h. Cells were then plated at a concentration of 2 × 10 4 cells per well and stimulated with increasing doses of Pam3CSK4 for 24 h. Cells were centrifuged and 20 μl supernatant was incubated with 180 μl QUANTI-Blue reagent at 37 °C for 30 min to 2 h. The levels of NF-κB-induced SEAP was measured in a microplate reader at 620 nm.
Protein isoform-isoform interaction network. Protein isoform-isoform interaction networks were generated on the basis of annotated protein-protein interaction and protein-domain interaction databases. In brief, all proteins and their amino acid sequences were obtained from the UCSC genome browser's Immunoprecipitation. HEK293 cells were transfected with 5 μg MyD88 and either 5 μg vector control, Flag-IRAK4-L or Flag-IRAK4-S for two days. Cells were lysed in RIPA. Flag antibody was added to cell lysates (1 mg) overnight at 4 °C and captured by the addition of anti-Flag M2 Affinity Gel (A2220; Sigma-Aldrich). The immune complexes were washed three times with lysis buffer followed by elution with Laemmli buffer. The bound proteins were separated by SDS-PAGE, transferred to nitrocellulose membranes, and analysed by immunoblotting for HA-MyD88. For endogenous immunoprecipitation of MyD88 and IRAK4, protein lysates from TF1 and HL60 cells were prepared by lysing cell pellets with CHAPS buffer (20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 150 mM NaCl, 2% CHAPS; all Sigma) containing protease and phosphatase inhibitors (Sigma) for 1 h on ice. Protein concentration was estimated using Bio-Rad protein assay. Equal amounts of protein lysates were incubated with primary antibody overnight at 4 °C, then an equal amount of protein A agarose beads (Rockland Immunochemicals) was added to all samples, followed by 1 h of incubation at 4 °C. The beads were washed three times with CHAPS, eluted with loading buffer supplemented with 2-mercaptoethanol (Sigma-Aldrich) and immunoblotting was performed.
Clonogenic progenitor assays. Clonogenic progenitor frequencies were determined by plating 1 × 10 3 cells per ml for cell lines and 3 × 10 5 cells per ml for normal bone marrow in methylcellulose (Methocult H4236; Stem Cell Technologies). Colonies were scored after 7 d. For clonogenic assays with primary MDS/AML cells, primary patient samples and healthy controls were plated in methylcellulose (Stem Cell Technologies H4435) with the CA-4948 and control, and colonies were counted after 14-17 d.
Xenografts. NOD-SCID IL-2Rɣ KO (NSG) mice were injected with 1 × 10 6 THP1 cells and treated with 12.5 mg kg
−1 of CA-4948 or control for five weeks. Mice were euthanized and assessed for tumour burden measurements. For primary patient-derived xenografts, NSG mice were irradiated (200 rads) 24 h before injection. Mononuclear cells from primary MDS patients were isolated by Ficoll separation. Two-to-five-million MNCs were administered via tail-vein injection. Three weeks later, bone marrow aspiration was performed and analysed by flow cytometry for the human cell engraftment. Mice were considered to be engrafted if they showed 0.1% or higher human derived CD45 + cells. The engrafted mice were randomized for treatment with CA-4948 or control for three weeks. Following treatment, bone-marrow aspirations and flow cytometry analysis for the abovementioned markers were performed. After primary engraftment, the NSG mice were euthanized. Cells were collected by crushing bones and spleen using a mortar and pestle and straining with 70 μm nylon mesh filter. Human cells were isolated by using Dynabeads Untouched Mouse T cells (Thermo-Fisher 11413D) and injected in mice previously irradiated with 200 rads. After eight weeks, the mice were euthanized and analysed for engraftment.
For shIRAK4 xenografts, THP1 cells were transduced with pLKO-scrambled-GFP, pLKO-shIRAK4-L-GFP or pLKO-shIRAK4-L/S-GFP and sorted for GFP expression 48 h later. One-million GFP + cells from each group were transplanted into NSG mice (n = 10). Bone marrow aspirations and bleeds were performed five weeks after transplantation and mice were euthanized when sick and assessed for GFP + proportions in bone marrow and peripheral blood. All mice were bred, housed and handled in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility of Cincinnati Children's Hospital Medical Center and Albert Einstein College of Medicine. The study is compliant with all relevant ethical regulations regarding animal research.
Haematologic toxicity assessment of CA-4948 in vivo. NSG mice received 12.5 mg per kg (body weight) CA-4948 (n = 9 mice) or vehicle (PBS; n = 7 mice) for 5 d per week for 12 weeks. Complete blood counts were determined at the end of the study.
RNA sequencing of MDS CD34
+ cells. Total RNA from MDS and control bone marrow CD34
+ cells was extracted using TRIzol with a linear acrylamide carrier, treated with DNase I (Life technologies) and purified using Agencourt RNAClean XP beads (Beckman Coulter). RNA quality was determined using an RNA 6000 Bioanalyzer pico kit (Agilent). A cDNA library was produced using a SMARTer library preparation protocol (Clontech). Sequencing (100-bp paired-end reads) was performed on an Illumina HiSeq4000. The reads were mapped to human genome GRCh37 using HISAT2 version 2.0.0-beta. Uniquely mapped read pairs were counted using htseq-count. The data have been deposited in the NCBI's Gene Expression Omnibus (GEO) repository (accession number: GSE114922).
IRAK4 exon 4 reporter cells. IRAK4 exon 4 (WT:
A at −3 position; Mutant: T at −3 position) and its flanking intronic sequences (100 nucleotides upstream and 100 nucleotides downstream from exon 4) were inserted into the EcoRI and BamHI sites of pFlareA vector, as previously described 57 . IRAK4 exon 4 is based on NCBI Refseq annotation, or exon 6 according to AltAnalyze Ensembl 72 annotation. pFlareA-exon4 vectors were linearized by DraIII and transfected into 293T cells. Cell colonies stably expressing the reporter were selected using 1 mg ml −1 G418 and stable expression of GFP and RFP.
Reagents. The IRAK1/4 inhibitor (IRAK1/4-Inh; Amgen) was purchased from Sigma-Aldrich (I5409). CA-4948 was received from Curis. Recombinant human IL-1β was purchased from PeproTech (200-01B).
Growth curves. Trypan blue exclusion was measured using an automated cell counter (Bio-Rad TC10). Cells were replenished with fresh medium, doxycycline and drug every fifth day.
Statistics and reproducibility.
Multiple independent experiments were performed to verify the reproducibility of all experimental findings. All quantitative data represent the mean ± s.e.m., unless otherwise stated. Unless otherwise indicated, two-tailed Student's t-tests were used to assess statistical significance for comparisons between two groups using Prism 8 (GraphPad software). The logrank test was used to determine P values for survival curves. All experiments were carried out at least twice, and the findings of all key experiments were reliably reproduced. All replicates and precise P values are provided in the figure and legends state the sample size and number of independent experiments. To knock out the gene of interest, at least three independent sgRNAs were employed to generate cell lines, and similar results were found in all cell lines.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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